-
Feb 5, 2024 | 
yahoo.com | Khushi Mandowara |Sriparna Roy
By Khushi Mandowara and Sriparna Roy(Reuters) -Merck said on Monday would buy Elanco Animal Health's aqua business for $1.3 billion in cash, strengthening its portfolio of aquatic pet health products. Share of Elanco rose more than 7% to $15.8 in premarket. Merck's animal health unit had acquired fish health product maker Scan aqua and fish conservation monitoring equipment makers Vaki and Antelliq Corp in 2019.
-
Feb 5, 2024 | 
today.westlaw.com | Sriparna Roy |Bhanvi Satija |Khushi Mandowara |Savio D'Souza
(Reuters) -Merck said on Monday would buy Elanco Animal Health's aqua business for $1.3 billion in cash, strengthening its portfolio of aquatic pet health products. Share of Elanco rose more than 7% to $15.8 in premarket.
-
Feb 2, 2024 | 
msn.com | Khushi Mandowara |Sneha K
Microsoft Cares About Your PrivacyMicrosoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.
-
Feb 2, 2024 | 
aol.com | Khushi Mandowara |Sneha K
Cigna raises 2024 profit view, beats Q4 earnings estimates on lower costsKhushi Mandowara and Sneha S KFebruary 2, 2024 at 3:03 AMBy Khushi Mandowara and Sneha S K(Reuters) - Health insurer Cigna Group raised its 2024 profit forecast on Friday after lower-than-expected medical costs and strong demand in its pharmacy benefit management unit helped it beat fourth-quarter profit estimates.
-
Feb 2, 2024 | 
streetinsider.com | Khushi Mandowara |Sneha K
1. CRWD2. TGT3. ROST4. SPY5. JWN6. BASE7. FERG8. BOX9. GILD10. HCP Tweet Share E-mail0 sharesFILE PHOTO: Signage for Cigna is pictured at a health facility in Queens, New York City, U.S., November 30, 2021.
-
Feb 2, 2024 | 
today.westlaw.com | Shinjini Ganguli |Sneha K |Khushi Mandowara
(Reuters) -Cigna said on Friday it expects higher pricing for some commercial health insurance plans and strength in its pharmacy benefit management (PBM) business from biosimilar and weight loss drugs, to help drive growth this year.
-
Jan 30, 2024 | 
yahoo.com | Sriparna Roy |Khushi Mandowara
By Sriparna Roy and Khushi Mandowara(Reuters) -Vertex Pharmaceuticals' experimental drug reduced acute, post-surgical pain without the risk of addiction, a major milestone in the company's decades-long efforts to bring a non-opioid pain medicine to market. The company plans to file for U.S. approval by mid-2024 for the drug, which works by blocking pain signals at its origin before they reach the brain. If approved, it could achieve annual sales of more than $5 billion, according to analysts.
-
Jan 30, 2024 | 
news.yahoo.com | Sriparna Roy |Khushi Mandowara
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston(Reuters) -Vertex Pharmaceuticals' experimental drug reduced acute, post-surgical pain without the risk of addiction, a major milestone in the company's decades-long efforts to bring a non-opioid pain medicine to market. The company plans to file for U.S. approval by mid-2024 for the drug, which works by blocking pain signals at its origin before they reach the brain.
-
Jan 30, 2024 | 
usnews.com | Sriparna Roy |Khushi Mandowara
By Sriparna Roy and Khushi Mandowara(Reuters) -Vertex Pharmaceuticals' experimental drug reduced acute, post-surgical pain without causing addiction, a major milestone in the company's decades-long efforts to bring a non-opioid pain medicine to market. The company plans to file for U.S. approval by mid-2024 for drug, which works by blocking pain signals at its origin before they reach the brain. If approved, it could achieve annual sales of more than $5 billion, according to analysts.
-
Jan 30, 2024 | 
sg.finance.yahoo.com | Sriparna Roy |Khushi Mandowara
Sriparna Roy and Khushi MandowaraUpdated 30 January 2024 at 9:15 am·2-min read(Adds analyst comment, updates share movement)By Sriparna Roy and Khushi MandowaraJan 30 (Reuters) -Vertex Pharmaceuticals' experimental drug reduced acute, post-surgical pain without causing addiction, a major milestone in the company's decades-long efforts to bring a non-opioid pain medicine to market.
